<DOC>
	<DOCNO>NCT03063827</DOCNO>
	<brief_summary>This study investigate change urothelial dysfunction sensory protein expression bladder urothelium time onabotulinumtoxin injection spinal cord injure ( SCI ) patient . The investigator plan enroll 30 chronic SCI patient neurogenic detrusor overactivity urinary incontinence treat single injection 200 U onabotulinumtoxinA detrusor . Video urodynamic study bladder mucosal biopsy perform baseline , 3 month , 6 month treatment . Bladder tissue investigate urothelial barrier inflammation proteins well sensory protein Western blotting , SCI patient 10 control , well successful fail treatment group . This study explore therapeutic efficacy single injection 200 U onabotulinumtoxinA neurogenic detrusor overactivity change urothelial sensory protein SCI patient successful fail treatment outcome .</brief_summary>
	<brief_title>Effect Botulinum Toxin A Neurogenic Detrusor Overactivity Chronic Spinal Cord Injured Patients</brief_title>
	<detailed_description>In recent decade , treatment neurogenic detrusor overactivity ( NDO ) onabotulinumtoxinA emerge alternative method management urological complication due spinal cord injury ( SCI ) multiple sclerosis . Injection 200-300 U onabotulinumtoxinA detrusor muscle reduce contractility , improve bladder compliance , restore urinary continence patient NDO . However , detrusor underactivity develop injection 300 U onabotulinumtoxinA improvement urodynamic quality life parameter last 9 month . Currently , 200 U single injection onabotulinumtoxinA detrusor recommend standard treatment NDO . However , therapeutic duration dosage NDO shorter 300 U injection . OnabotulinumtoxinA effectively improve low urinary tract symptom inhibit signal transmission neuromuscular neuroglandular junction . OnabotulinumtoxinA cleave synaptosome-associated protein 25 inhibits signal transmission disrupt fusion neurotransmitter- containing vesicle neuronal wall . In urinary bladder , release acetylcholine pre- postganglionic parasympathetic nerve block onabotulinumtoxinA administration . This toxin also find modulate afferent activity bladder associate reduced urgency urgency urinary incontinence symptom NDO patient . Although impact onabotulinumtoxinA sympathetic nervous system within urinary bladder unclear , inhibitory effect release norepinephrine α- β3-adrenoreceptors ( β3-ARs ) regulate bladder neck contraction detrusor relaxation , respectively . A previous study report decreased expression adhesion junction proteins E-cadherin zonula occludens-1 ( ZO-1 ) , respectively , increase suburothelial inflammation apoptosis patient chronic SCI bladders.The urothelial inflammation dysfunction SCI bladder might also alter sensory protein expression , purinergic receptor P2X3 , transient receptor potential vallinoid receptor subfamily 1 , adenosine triphosphate , nitric oxide . Urothelial dysfunction might also result increased excitability C-fibers become predominantly afferent nerve micturition reflex SCI . In human NDO , level bladder P2X2 , P2X3 , muscarinic receptor M2 M3 reduce detrusor onabotulinumtoxinA injection , suggest toxin inhibits DO inhibit sensory motor arm micturition reflex . In addition , β3-ARs know promote urine storage bladder induce detrusor relaxation animal human bladder . In human , β3-AR predominant β-receptor subtype urinary bladder . There report β3-AR change SCI bladder urothelium onabotulinumtoxin treatment . After onabotulinumtoxinA injection , patient may symptom-free period 3-6 month symptom relapse . Most study onabotulinumtoxinA NDO come animal model , human study note . The current study investigate change urothelial dysfunction sensory protein expression bladder urothelium time single onabotulinumtoxin injection SCI patient . Materials Methods A total 26 patient chronic SCI cause NDO urinary incontinence treat single injection 200 U onabotulinumtoxinA detrusor muscle . All patient present urinary incontinence without difficult bladder empty . In patient receive detrusor injection , clean intermittent catheterization suggest possible mode urinary management treatment . The current study approve Institutional Review Board Ethics Committee Buddhist Tzu Chi General Hospital ( IRB:098-53 ) . Each patient inform study rationale procedure , write informed consent participate obtain bladder procedure . Video urodynamic study All patient receive video urodynamic study ( VUDS ) enrollment . Bladder urethral dysfunction classify presence DO coordinate dyssynergic urethral sphincter activity . Patients urinary tract infection properly treat scheduled onabotulinumtoxinA injection . VUDS result interpret accord recommendation International Continence Society . VUDS parameter include maximum flow rate ( Qmax ) , detrusor void pressure Qmax ( Pdet ) , cystometric bladder capacity ( CBC ) , voided volume ( Vol ) , post-void residual ( PVR ) volume . OnabotulinumtoxinA injection All patient receive 200 U onabotulinumtoxinA 20 mL normal saline ( BOTOX® , 100 U/vial , Allergan Inc. , Irvine , USA ) operation room rigid cytoscopic injection ( 22 Fr , Richard Wolf , Knittlingen , Germany ) 40 site bladder wall , spar trigoneAfter injection , urethral Foley catheter routinely insert remove next morning patient discharge . Broad spectrum antibiotic prescribe 3 treatment . After onabotulinumtoxinA injection , four bladder cold-cup biopsy take randomly posterior wall 2 cm interureteric ridge , bladder mucosa submucosa take prevent bladder perforation ; erythematous inflammatory bladder mucosa avoid . One bladder biopsy specimen patient send pathology department exclude possibility carcinoma situ . The remain three specimens patient store optimum cutting temperature liquid nitrogen immunohistochemistry study . Patient follow-up outcome assessment Patients follow OPD monthly , VUDS assessment bladder void condition satisfaction treatment perform 3 6 month treatment . If CBC increase 50 % baseline value , treatment outcome consider successful ; otherwise , outcome consider failure time-point . Ten female patient stress-related urinary incontinence without frequent urgency serve control . All control patient confirm free bladder outlet obstruction DO VUDS . Control bladder tissue obtain anti-incontinence surgery process SCI patient . Male patient select serve control prostate could cause bladder outlet obstruction affect urothelial function . Immunofluorescence Bladder tissue sample SCI patient control examine change urothelial E-cadherin ( adhesive protein ) , ZO-1 ( junction protein ) , mast cell activation ( tryptase ) level immunofluorescence ; cellular apoptosis examine terminal deoxynucleotidyl transferase dUTP nick end-labeling assay . These procedure perform similar previous study , 6-μm thickness tissue section . Urinary bladder specimen immerse fixed 1 h ice-cold 4 % formaldehyde phosphate-buffered saline ( pH 7.4 ) rinse ice-cold phosphate-buffered saline contain 15 % sucrose 12 h. Biopsy specimens embed optimum cut temperature medium store −80 °C . Four section per specimen cut use cryostat thickness 8 μm collect new silane III-coated glass slide ( Muto Pure Chemicals Co. , Ltd , Tokyo , Japan ) . Sections postfixed acetone −20 °C block rabbit serum . The section incubate overnight 4 °C antihuman E-cadherin ( BD Biosciences , San Jose , CA , USA ) tryptase ( Chemicon , Temecula , CA , USA ) primary antibody . After rinse section 0.1 % Tween-20 BPS , rabbit antimouse-conjugated fluorescein isothiocyanate secondary antibody ( DakoCytomation Denmark A/S , Glostrup , Denmark ) apply incubated section 1 h. Finally , section counterstained 4',6-diamidino-2-phenylindole ( Sigma Chemical Co. , St. Louis , MO , USA ) . Negative control include isotype primary antibody . We obtain mean , maximum , range , standard deviation stain intensity percent positive area measurement use three random hot spot within specimen . Immunofluorescence quantification determine four consecutive high-power field ( 400X ) area great density . Immunofluorescence ( tryptase terminal deoxynucleotidyl transferase dUTP nick end-labeling ) assay quantified count number positively stain cell per unit area ( 4 μm2 ) show percentage . The intensity E-cadherin ( ﬂuorescence microscopy ) ZO-1 ( confocal microscopy ) fluorescence quantify use Image J . Western blotting use ass level sensory protein bladder mucosa specimen . Primary antibody include P2X3 ( 1:2000 ) , endothelial nitric oxide synthase [ eNOS ] ( 1:1000 ) , M2 ( 1:1000 ) , M3 ( 1:500 ) , GAPDH ( 1:100000 ; internal control ) GeneTex ( Irvine , CA , USA ) ; inducible NOS [ iNOS ] ( 1:1500 ; ThermoFisher , Rockford , IL , USA ) ; β3-AR ( 1:1000 ; Abcam , Cambridge , UK ) . Donkey antigoat ( β3-AR ) goat antirabbit ( protein ) IgG-horseradish peroxidase ( 1:3000 ; Santa Cruz Biotechnology , Dallas , TX , USA ) secondary antibody use . The scanned ﬁlm gel electrophoresis quantiﬁed use gel documentation system ( Quantity One Version 4.6.2 , Bio-Rad Laboratories , Hemel Hempstead , Herts , UK ) . Procedures similar describe previous study . Statistical Analysis Continuous variable present mean ± standard deviation , categorical data present number percentage . Eligible SCI patient group accord treatment outcome compare control . Differences level functional protein urothelium baseline 3 6 month onabotulinumtoxinA injection analyze use paired Student 's t-test . Differences immunofluorescence Western blot sensory protein successful fail treatment group analyze use Kruskal-Wallis test . In order clarify roles urothelial sensory protein NDO , correlation analysis use linear regression also perform , include VUDS urothelial dysfunction parameter . All calculation do use SPSS Windows version 16.0 ( SPSS , Chicago , IL , USA ) . Differences consider statistically significant P value less 0.05 .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>patient chronic SCI cause NDO urinary incontinence patient present urinary incontinence patient know allergic onabotulinumtoxinA patient follow regularly active urinary tract infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>